ERBB2 and breast cancer: The surface molecules that can guide the binding of engineered EVs to BC cells include anti-human HER2 antibodies, mesenchymal-epithelial transition factor-binding peptide, aptamer AS1411, and lipidomimetic chain-conjugated HA [233–236].